Analyst Consensus ?
ConsensusBuy31 ratings
Bullish2580.6%
Neutral619.4%
Bearish00.0%
McKesson Corporation · MCK · FY2025 Q3 · Calendar Q1 2025
McKesson posts strong Q3 growth and expands specialty platform
The quarter supports a constructive view of McKesson's growth trajectory: specialty pharmaceutical demand, oncology services, prescription technology, and the PRISM Vision expansion were highlighted as growth drivers. The main counterweights are softer medical-surgical demand and execution, regulatory, and policy risks.
Reported After market closeNYSEHealthcare
$117.15B market cap
80quality score
Earnings scorecard
Reported versus consensus
Reported EPS
—
Consensus $8.60
EPS surprise
—
Reported versus consensus
Reported revenue
—
Consensus $95.86B
Revenue surprise
—
Reported versus consensus
Market reaction
event-close to next-session close
Stock move
-1.2%
Event window
SPY move
+0.3%
Same window
Abnormal move
-1.5%
Stock minus SPY
Volume
2.5×
Versus trailing sessions
Subsequent drift
+7.4%
Up to 20 sessions
MCKSPY benchmark
Ask FN2 about MCK FY2025 Q3
Transcript, numbers and history already loaded
What drove MCK's -1.2% move after FY2025 Q3 earnings?What changed in MCK's guidance and outlook in FY2025 Q3?Give me the bull and bear case for MCK after FY2025 Q3 earnings.
Free account. Your question opens in FN2 with this report's transcript and numbers attached.
Transcript intelligence
What changed
Management reported stronger Q3 operating performance, raised and narrowed FY2025 adjusted EPS guidance, announced the PRISM Vision acquisition, and highlighted continued oncology, prescription-technology, and cost-optimization progress.
Guidance delta
Management raised and narrowed FY2025 adjusted EPS guidance to $32.55-$32.95.
Key takeaways
- Q3 revenue grew 18% to $95.3 billion; adjusted operating profit rose 16% to $1.5 billion.
- U.S. pharmaceutical and specialty demand drove growth, while medical-surgical revenue declined 3%.
- PRISM Vision adds a retina and ophthalmology platform; cost-optimization savings remain a focus.
Management priorities
- Complete the business rationalization plan by H1 FY2026.
- Scale the retina and ophthalmology platform after the PRISM Vision acquisition.
- Expand oncology and prescription-technology services.
- Continue investments in automation, AI, cloud, and data analytics.
Follow MCK with an agent that reads every filing, transcript, and price print. Free to start.
Try FN2 freeEarnings History
Estimate
Beat
Miss
Match
Analyst 52W Price Targets
$1,004.84Current
$257Low
$831Average
$1,200High
Latest persisted target per named analyst; persisted current price from FN2's market snapshot as of Oct 17, 2026. Not an FN2 forecast.
Firm-level rating actions
FMP grade actions identify the grading firm, not a named analyst.
| Firm | Rating | Prior rating | Action | Date |
|---|---|---|---|---|
| UBS | Buy | Buy | Maintain | Oct 16, 2026 |
| Leerink Partners | Outperform | Outperform | Maintain | Oct 7, 2026 |
| RBC Capital | Sector Perform | Sector Perform | Maintain | Sep 14, 2026 |
| Barclays | Overweight | Overweight | Maintain | Aug 19, 2026 |
| Wells Fargo | Equal Weight | Equal Weight | Maintain | Aug 11, 2026 |
| TD Cowen | Buy | Buy | Maintain | Aug 6, 2026 |
| Evercore ISI Group | Outperform | Outperform | Maintain | Aug 6, 2026 |
| Citigroup | Buy | Buy | Maintain | Jul 24, 2026 |
| JP Morgan | Overweight | Overweight | Maintain | May 8, 2026 |
| B of A Securities | Buy | Buy | Maintain | Apr 6, 2026 |
| Mizuho | Neutral | Neutral | Maintain | Feb 5, 2026 |
| Morgan Stanley | Overweight | Overweight | Maintain | Nov 6, 2025 |
| Baird | Outperform | Outperform | Maintain | Nov 6, 2025 |
| Jefferies | Buy | Buy | Maintain | Oct 14, 2025 |
| Deutsche Bank | Buy | Buy | Maintain | Sep 24, 2025 |
| Argus Research | Buy | Buy | Maintain | Jun 24, 2024 |
| Credit Suisse | Outperform | Outperform | Maintain | Aug 11, 2023 |
| Cowen & Co. | Outperform | Outperform | Maintain | Apr 18, 2022 |
| Goldman Sachs | Buy | Buy | Maintain | May 7, 2021 |
| Guggenheim | Buy | Buy | Maintain | May 27, 2020 |
| CFRA | Buy | Buy | Maintain | May 20, 2020 |
| Standpoint Research | Buy | Hold | Upgrade | Jul 10, 2018 |
| Leerink Swann | Market Perform | Market Perform | Maintain | May 29, 2018 |
| Bank of America | Buy | Buy | Maintain | Apr 11, 2018 |
| Needham | Hold | Hold | Maintain | Apr 4, 2017 |
| Avondale Partners | Market Outperform | Market Perform | Upgrade | Jan 18, 2017 |
| Raymond James | Market Perform | Outperform | Downgrade | Jan 12, 2016 |
| S&P Capital IQ | Buy | Strong Buy | Downgrade | Jan 13, 2014 |
| FBR Capital | Outperform | Outperform | Maintain | Oct 29, 2013 |
| ISI Group | Strong Buy | Buy | Upgrade | Oct 24, 2013 |
| Sterne Agee | Buy | Buy | Maintain | Sep 18, 2013 |
Named analyst price targets
Upside is calculated against the persisted current price $1,004.84. FMP does not supply a rating on these named-analyst rows.
| Firm | Analyst | 52W target | Price when posted | Upside | Date |
|---|---|---|---|---|---|
| UBS | Analyst unavailable | $1,200 | $998.64 | +19.4% | Oct 16, 2026 |
| Morgan Stanley | Erin Wright | $977 | $915.45 | -2.8% | Oct 6, 2026 |
| Barclays | Glen Santangelo | $1,000 | $869.26 | -0.5% | Aug 19, 2026 |
| RBC Capital | Ryan Halsted | $845 | $869.26 | -15.9% | Aug 19, 2026 |
| Wells Fargo | Stephan Baxter | $933 | $879.87 | -7.1% | Aug 11, 2026 |
| Robert W. Baird | Analyst unavailable | $1,015 | $843.89 | +1.0% | Aug 6, 2026 |
| UBS | Kevin Caliendo | $1,050 | $744.46 | +4.5% | May 8, 2026 |
| Deutsche Bank | George Hill | $875 | $763.9 | -12.9% | May 8, 2026 |
| Raymond James | Analyst unavailable | $970 | $930.31 | -3.5% | Mar 5, 2026 |
| Leerink Partners | Michael Cherny | $1,085 | $930.22 | +8.0% | Mar 5, 2026 |
| Barclays | Analyst unavailable | $1,050 | $946.47 | +4.5% | Feb 18, 2026 |
| Morgan Stanley | Analyst unavailable | $966 | $826.62 | -3.9% | Jan 29, 2026 |
| Robert W. Baird | Eric Coldwell | $968 | $833.36 | -3.7% | Jan 14, 2026 |
| Barclays | Analyst unavailable | $960 | $797.93 | -4.5% | Dec 8, 2025 |
| Evercore ISI | Analyst unavailable | $1,000 | $852.02 | -0.5% | Nov 6, 2025 |
| UBS | Kevin Caliendo | $920 | $801.3 | -8.4% | Oct 27, 2025 |
| Jefferies | Analyst unavailable | $900 | $769.49 | -10.4% | Oct 13, 2025 |
| Wells Fargo | Stephen Baxter | $772 | $659.01 | -23.2% | Aug 13, 2025 |
| Wells Fargo | Stephen Baxter | $766 | $714.88 | -23.8% | Jun 3, 2025 |
| Jefferies | Rob Dickerson | $715 | $541.15 | -28.8% | Nov 19, 2024 |
| Robert W. Baird | Eric Coldwell | $688 | $526.54 | -31.5% | Nov 7, 2024 |
| Deutsche Bank | George Hill | $579 | $479.16 | -42.4% | Sep 25, 2024 |
| Robert W. Baird | Eric Coldwell | $531 | $505 | -47.2% | Sep 24, 2024 |
| Wells Fargo | Stephen Baxter | $535 | $511.17 | -46.8% | Sep 13, 2024 |
| Leerink Partners | Michael Cherny | $665 | $514.75 | -33.8% | Sep 6, 2024 |
| Bank of America Securities | Michael Cherny | $635 | $526.5 | -36.8% | Sep 5, 2024 |
| Mizuho Securities | Ann Hynes | $570 | $617.51 | -43.3% | Aug 8, 2024 |
| Robert W. Baird | Eric Coldwell | $694 | $589.53 | -30.9% | Jul 9, 2024 |
| Argus Research | David Toung | $670 | $608.72 | -33.3% | Jun 24, 2024 |
| Robert W. Baird | Eric Coldwell | $679 | $549.26 | -32.4% | May 29, 2024 |
| Argus Research | David Toung | $570 | $527.28 | -43.3% | Apr 10, 2024 |
| Robert W. Baird | Eric Coldwell | $603 | $534.79 | -40.0% | Apr 5, 2024 |
| Robert W. Baird | Eric Coldwell | $567 | $494.01 | -43.6% | Feb 8, 2024 |
| Mizuho Securities | Ann Hynes | $450 | $515.03 | -55.2% | Feb 7, 2024 |
| Morgan Stanley | Analyst unavailable | $426 | $370.98 | -57.6% | Feb 2, 2023 |
| Morgan Stanley | Analyst unavailable | $420 | $384.01 | -58.2% | Jan 6, 2023 |
| UBS | Kevin Caliendo | $380 | $322.86 | -62.2% | May 23, 2022 |
| Morgan Stanley | Ricky Goldwasser | $370 | $323.25 | -63.2% | Apr 16, 2022 |
| Robert W. Baird | Eric Coldwell | $340 | $258.02 | -66.2% | Feb 2, 2022 |
| Morgan Stanley | Ricky Goldwasser | $292 | $232.69 | -70.9% | Dec 17, 2021 |
| Barclays | Steven Valiquette | $290 | $230.35 | -71.1% | Dec 9, 2021 |
| Argus Research | David Toung | $270 | $219.39 | -73.1% | Nov 8, 2021 |
| Goldman Sachs | Robert Jones | $257 | $195.97 | -74.4% | May 7, 2021 |
Track every rating change on MCK the moment it posts. Free to start.
Start freeCompany context
Snapshot as of publicationMcKesson Corporation is a prominent global provider of healthcare services, operating extensively in both the United States and international markets. Its diverse operations are strategically organized into four key business segments. The U.S. Pharmaceutical division plays a crucial role in the distribution of a comprehensive array of pharmaceutical products, encompassing branded, generic, specialty, biosimilar, and over-the-counter medications, alongside other health-related merchandise. This segment also delivers specialized support to community-based oncology and other specialty medical practices through practice management tools, technology solutions, clinical guidance, and broader business services. Furthermore, it assists pharmacies with consulting, outsourcing, and technology services, while also furnishing financial, operational, and clinical software solutions.…
Historical context
All MCK earningsLatest beats and misses
Who reports nextBeat on EPS
Get the MCK recap when the next report posts
One email per quarter with the scorecard, the market reaction and what changed on the call. No account needed.
Sources
- Earnings call transcript and parsed analysis · 2026-05-11T10:29:34.698584+00:00
- FN2 earnings calendar · 2025-01-22T00:04:22.296664+00:00
- Polygon adjusted daily market bars · 2026-10-17T12:40:41.778324+00:00
- Financial Modeling Prep analyst price-target consensus and quote snapshot · 2026-10-17T12:40:41.775570+00:00
Methodology
Reported and consensus figures come from FN2's earnings event records. Market reaction and volume are calculated from daily adjusted bars around the event; abnormal move subtracts the SPY move over the same window.
Analyst target low, average, and high values are derived at request time from each named analyst's latest persisted FMP target. The current-price marker comes from FN2's persisted market snapshot. They are sell-side estimates, not an FN2 valuation or recommendation.
Transcript intelligence is a structured synthesis of the current and prior earnings-call analyses. Missing values stay missing and are never estimated.
By FN2 Research · Updated · As of 2026-10-17. For educational purposes only; not investment advice.